8-K: Calidi Biotherapeutics Secures $2 Million in Direct Offering and Private Placement

Calidi Biotherapeutics has successfully priced a $2 million registered direct offering and concurrent private placement to fund working capital and clinical trials.

Summary

• Calidi Biotherapeutics has entered into a securities purchase agreement with institutional investors.
• The company will sell 2,050,000 shares of common stock at $1.00 per share in a registered direct offering.
• In a concurrent private placement, Calidi will issue Series E and Series F warrants, each for up to 2,050,000 shares.
• Series E warrants have an exercise price of $1.13, are exercisable after six months, and expire one year after exercisability.
• Series F warrants also have an exercise price of $1.13, are exercisable after six months, and expire five years after exercisability.
• The gross proceeds from the offering are expected to be approximately $2 million.
• Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent.
• The company intends to use the net proceeds for working capital, general corporate purposes, and clinical trials.

Sentiment

Score: 7

Explanation: The document is generally positive as it details a successful capital raise, but there are some risks associated with dilution and the inherent uncertainty of clinical trials. The sentiment is moderately positive.

Positives

• The company has successfully secured $2 million in funding.
• The funds will be used for working capital and clinical trials.
• The offering includes both common stock and warrants, potentially attracting a wider range of investors.
• The warrants have a defined exercise price and term, providing clarity for investors.

Negatives

• The offering involves the issuance of new shares, which may dilute existing shareholders.
• The warrants, if exercised, could further dilute existing shareholders.
• The company is relying on a placement agent, which may incur additional fees.

Risks

• The company may not be able to raise sufficient capital to support its current and anticipated clinical trials.
• Early results of clinical trials may not predict final results.
• The company may not receive FDA approval for its therapeutic candidates.
• The offering involves the issuance of new shares, which may dilute existing shareholders.
• The warrants, if exercised, could further dilute existing shareholders.

Future Outlook

Calidi intends to use the net proceeds from the offerings for working capital, general corporate purposes, and pre-clinical and clinical trials.

Industry Context

This capital raise is typical for a clinical-stage biotechnology company seeking to fund ongoing research and development. The use of a registered direct offering and concurrent private placement is a common strategy to raise capital from institutional investors.

Comparison to Industry Standards

• The use of a registered direct offering combined with a private placement of warrants is a fairly standard approach for biotech companies to raise capital.
• The terms of the warrants, including the exercise price and expiration dates, are within the typical range for such instruments in the biotech sector.
• Comparable companies often use similar financing methods to fund clinical trials and operations.
• The size of the offering, $2 million, is relatively small compared to some larger biotech financings, but is appropriate for a company at Calidi's stage.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• The company will have additional capital to fund operations and clinical trials.
• The company's ability to advance its therapeutic candidates may be improved.

Next Steps

• The closing of the offering is expected to occur on or about October 24, 2024.
• The company will use the net proceeds for working capital, general corporate purposes, and clinical trials.
• The company will file a prospectus supplement with the SEC.

Key Dates

Keywords

Calidi Biotherapeutics, registered direct offering, private placement, common stock, warrants, immunotherapies, clinical trials, biotechnology, Ladenburg Thalmann, capital raise